Quick Answer
What is ETS surgery (Endoscopic Thoracic Sympathectomy)? ETS is an endoscopic surgical procedure that accesses the thoracic sympathetic nerve ganglia through the chest cavity to treat excessive palm sweating (palmar hyperhidrosis) and facial flushing (facial hyperhidrosis). While highly effective for palmar sweating with a success rate exceeding 95%, compensatory sweating (increased sweating on the trunk, legs, and abdomen) affects 50–90% of patients and is considered a significant unwanted effect. For this reason, ETS should be regarded as a last resort, reserved for severe cases that have not responded to other treatments.
What Is Hyperhidrosis? Why Does ETS Come Into Consideration?
Hyperhidrosis is a condition characterized by excessive sweating that occurs without any physiological necessity. It can severely impair daily functioning, social relationships, and quality of life. Hyperhidrosis is divided into two main categories: primary hyperhidrosis (unknown cause, often genetically predisposed, localized sweating in specific areas) and secondary hyperhidrosis (caused by an underlying medical condition or medication, with generalized sweating).
ETS is applied only to cases of primary hyperhidrosis — particularly palmar (hand), axillary (underarm), and facial (face/head) types. ETS is not indicated for secondary hyperhidrosis; the underlying cause must be treated first. At Virtuana Clinic, every patient undergoes detailed hyperhidrosis-type classification prior to ETS.
The Anatomical Basis of ETS: The Sympathetic Nervous System
The sweating reflex is controlled by the sympathetic nervous system. The sweat glands of the hands and face are stimulated by nerve fibers from the thoracic sympathetic ganglia — primarily the T2 (second thoracic) and T3 ganglia. ETS permanently blocks the transmission of impulses to the sweat glands of the hand by interrupting these ganglia (via clamping, resection, or cauterization).
Different ganglion levels affect different regions:
- T2 level: Sweat glands of the face and head; facial flushing
- T3 level: Palm of the hand; palmar hyperhidrosis
- T4 level: Underarm; axillary hyperhidrosis (partial)
Modern ETS protocols favor the narrowest possible procedure (affecting the fewest ganglia) to minimize compensatory sweating. Limited clamping at T4 and T3 levels significantly reduces the risk of compensatory sweating compared to extensive resection including T2.
The ETS Procedure: Technical Details
ETS is an endoscopic thoracic surgical procedure performed under general anesthesia. The standard procedure steps are as follows:
- Anesthesia induction: General anesthesia with double-lumen intubation; the lung is collapsed during the procedure
- Trocar placement: 2–3 trocars are inserted through small incisions in the axilla; the thoracoscope and instruments are introduced into the chest cavity
- Visualization of the sympathetic chain: The sympathetic ganglion chain at the T2–T4 vertebral level is identified under endoscopic guidance
- Ganglion intervention: At the target level, sympathetic connections are interrupted by clamp placement, high-frequency ablation (RF), or cut-and-cauterize technique
- Contralateral side: The opposite side is treated in the same session (bilateral)
- Closure: The lung is re-inflated, trocars are removed, and incisions are closed
The procedure typically lasts 30–60 minutes. An average of one overnight stay in intensive care or observation is required post-operatively; most patients are discharged within 1–2 days.
ETS Success Rates: Clinical Data
ETS is one of the treatments with the highest success rates worldwide for palmar hyperhidrosis. However, the success rate and patient satisfaction vary considerably depending on the area treated:
| Hyperhidrosis Type | Success Rate | Patient Satisfaction | Compensatory Sweating |
|---|---|---|---|
| Palmar (hand) | 95–98% | 75–85% (long-term) | 52–90% (variable) |
| Axillary (underarm) | 70–85% | 55–70% | 60–85% |
| Facial (facial flushing) | 80–90% | 65–75% | 70–85% |
A critical point stands out when interpreting these data: despite high success rates, long-term patient satisfaction is lower. The primary reason for this gap is compensatory sweating.
Compensatory Sweating: The Most Important Risk of ETS
Compensatory sweating (CS) is the result of the body's attempt to rebalance its thermoregulation system after ETS. When sympathetic nerve interruption silences the sweat glands of the hand or face, the body compensates by increasing sweating in other areas. CS most commonly affects the anterior trunk, lower back, thighs, and legs.
The severity of CS varies greatly from patient to patient:
- Mild CS (30–40% of patients): A noticeable but non-disruptive increase in sweating; most patients can cope with this comfortably
- Moderate CS (30–40% of patients): Sweating that is uncomfortable but does not cause severe social or functional limitation
- Severe CS (15–25% of patients): Sweating far more bothersome than the original hand sweating, causing social and functional impairment; a significant proportion of these patients regret the surgery
Compensatory sweating risk cannot be predicted. No preoperative test can reliably forecast which patient will develop severe CS. This uncertainty demands a deep ethical and clinical dialogue with the patient before making the ETS decision.
Alternative Treatments to Try Before ETS
ETS is an irreversible surgical procedure. For this reason, less invasive, reversible treatments for hyperhidrosis management should be systematically tried first; surgical evaluation should only be considered if they prove inadequate. The recommended treatment ladder is as follows:
| Treatment Step | Method | Efficacy | Reversible? |
|---|---|---|---|
| Step 1 | Topical aluminum chloride hexahydrate (20–25% antiperspirants) | Mild–moderate: 30–50% reduction | Yes |
| Step 2 | Iontophoresis (temporary sweat gland blockade via electric current) | Moderate: 50–80% reduction (with regular use) | Yes (temporary effect) |
| Step 3 | Botulinum toxin injection (hand, underarm) | High: 82–95% reduction (duration 6–12 months) | Yes (temporary effect) |
| Step 4 | Oral anticholinergics (oxybutynin, glycopyrrolate) | Moderate–high (50–80%); systemic side effects may be an issue | Yes |
| Step 5 (last resort) | ETS surgery | Very high (95%+, palmar) | NO — permanent / difficult to reverse |
ETS Indications: Who Is a Surgical Candidate?
The decision to proceed with ETS must be made with extreme care. International guidelines recommend the following criteria for surgery:
- Severe primary palmar or facial hyperhidrosis (inadequate response to first-line treatment)
- Documented failure of at least 2 different conservative treatments
- Patient-reported severe impairment of daily life, social functioning, and work performance
- Full patient counseling regarding compensatory sweating and other risks, with establishment of realistic expectations
- Fitness for general anesthesia (adequate pulmonary function, no contraindications to thoracic surgery)
ETS Contraindications and Risks
Situations in which ETS should not be performed and procedure-specific risks include:
- Absolute contraindications: Pleural adhesions (pleurodesis), advanced lung disease, coagulation disorder
- Relative contraindications: Obesity (higher CS risk), secondary hyperhidrosis diagnosis, anticipated severe compensatory sweating
- Procedure-specific risks: Horner syndrome (1–3%), pneumothorax, compensatory sweating (50–90%), vascular injury during surgery (rare)
- Horner syndrome risk: If the T2 level is inadvertently over-damaged, a permanent complication presenting as eyelid drooping (ptosis), pupil constriction (miosis), and decreased sweating may occur.
Life After ETS: Realistic Expectations
Published data on the long-term experience of patients who have undergone ETS present a mixed picture. In long-term follow-up studies involving large patient cohorts in Sweden (Drott et al.), 93.4% of patients were satisfied with the surgery, yet 67% reported experiencing compensatory sweating. An important finding was that the higher the disease severity before surgery, the higher the post-operative satisfaction.
From the Virtuana Clinic perspective, the majority of patients presenting for ETS surgery have previously been treated with botulinum toxin or have been assessed for it. The hot and humid summer climate of Kocaeli exacerbates palmar hyperhidrosis symptoms, contributing to relatively high demand for ETS in the region. Nevertheless, we prioritize managing our patients with reversible treatments such as botulinum toxin and iontophoresis first; if an adequate response cannot be achieved, we refer for surgical consultation.
Botulinum Toxin as an Alternative to ETS: Efficacy and Practical Application
Botulinum toxin type A temporarily blocks the sweat glands' response to acetylcholine stimulation, thereby inhibiting sweating. Although palmar application is technically demanding (requiring multiple injections and pain management), it achieves efficacy close to ETS with an 82–95% success rate in experienced hands. The duration of effect is 6–12 months; while it does not provide a permanent result, it carries no risk of compensatory sweating and is fully reversible.
At Virtuana Clinic in Izmit/Kocaeli, botulinum toxin injection for palmar hyperhidrosis is performed painlessly using surface anesthesia (topical EMLA cream or ice) or nerve block. In patients who undergo treatment at regular intervals, palmar sweating can be kept under control throughout the warm season.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.